跳至主要内容
临床试验/NCT00999063
NCT00999063已完成不适用

Prevalence of GERD in Patients With upperGITsymptoms in Thailand

AstraZeneca1 个研究点 分布在 1 个国家目标入组 4,108 人开始时间: 2009年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
4,108
试验地点
1
主要终点
Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms

研究概览

简要总结

This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provision of informed consent prior to any study specific procedures
  • Female or male aged at least 18 years
  • Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

排除标准

  • Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site
  • Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months

结局指标

主要结局

Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms

次要结局

  • Response to various treatments for patients who have been diagnosed of GERD

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验